The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Inclusion Criteria: * Participant has operable Stage I-IIIa invasive breast cancer of the following subtype: ER-positive, HER2-negative tumor with histologic grade 2 or 3 and Ki67 ≥ 15% * Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam * Participant consents to provide an existing tissue sample or to have a core needle biopsy before drug administration * Participant consents to provide tissue samples following drug administration by a second core needle biopsy or from a surgical specimen * Participant must have adequate organ function Exclusion Criteria: * Participant has received any prior chemotherapy, biological therapy or radiotherapy for breast cancer * Participant has a known hypersensitivity to the components of study drugs or their analogs, including hypersensitivity to macrolide antibiotics (e.g. clarithromycin, erythromycin, azithromycin). * Participant has poorly controlled diabetes mellitus, or requires insulin for glucose control. * Participant is unable to swallow capsules and/or absorb oral medications * Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study. * Participant is known to be Human Immunodeficiency Virus (HIV)-positive * Participant has known history of active Hepatitis B or C. * Participant is concurrently using growth hormone (GH) or growth hormone inhibitors * Participant has significant or uncontrolled cardiovascular disease, including heart failure, unstable angina, or a myocardial infarction within the last 6 months